Contrasting Hyperfine (NASDAQ:HYPR) & Echo Therapeutics (OTCMKTS:ECTE)
Contrasting Hyperfine (NASDAQ:HYPR) & Echo Therapeutics (OTCMKTS:ECTE)
Echo Therapeutics (OTCMKTS:ECTE – Get Rating) and Hyperfine (NASDAQ:HYPR – Get Rating) are both medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their risk, dividends, profitability, earnings, analyst recommendations, valuation and institutional ownership.
Echo Treateutics(场外交易代码:ECTE-GET Rating)和超精细(纳斯达克:HYPR-GET Rating)都是医疗公司,但哪项业务更优越?我们将根据这两家公司的风险、股息、盈利能力、收益、分析师建议、估值和机构所有权的强弱对它们进行比较。
Valuation & Earnings
估值与收益
This table compares Echo Therapeutics and Hyperfine's revenue, earnings per share (EPS) and valuation.
下表比较了Echo Treeutics和HyperFine的收入、每股收益(EPS)和估值。
Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
Echo Therapeutics | N/A | N/A | N/A | N/A | N/A |
Hyperfine | $1.50 million | 40.46 | -$64.85 million | ($3.59) | -0.24 |
总收入 | 价格/销售额比 | 净收入 | 每股收益 | 市盈率 | |
回声治疗学 | 不适用 | 不适用 | 不适用 | 不适用 | 不适用 |
超细 | 150万美元 | 40.46 | -6,485万元 | ($3.59) | -0.24 |
Echo Therapeutics has higher earnings, but lower revenue than Hyperfine.
Echo Treateutics的收益更高,但收入比HyperFine低。
Insider & Institutional Ownership
内部人与机构所有权
Profitability
盈利能力
This table compares Echo Therapeutics and Hyperfine's net margins, return on equity and return on assets.
此表比较了Echo Treeutics和HyperFine的净利润率、股本回报率和资产回报率。
Net Margins | Return on Equity | Return on Assets | |
Echo Therapeutics | N/A | N/A | N/A |
Hyperfine | -1,479.40% | -54.01% | -49.87% |
净利润率 | 股本回报率 | 资产回报率 | |
回声治疗学 | 不适用 | 不适用 | 不适用 |
超细 | -1,479.40% | -54.01% | -49.87% |
Analyst Ratings
分析师评级
This is a breakdown of current ratings and recommmendations for Echo Therapeutics and Hyperfine, as provided by MarketBeat.
这是MarketBeat提供的Echo治疗和HyperFine的当前评级和建议的细目。
Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
Echo Therapeutics | 0 | 0 | 0 | 0 | N/A |
Hyperfine | 0 | 1 | 2 | 0 | 2.67 |
销售评级 | 保持评级 | 购买评级 | 强劲的买入评级 | 评级分数 | |
回声治疗学 | 0 | 0 | 0 | 0 | 不适用 |
超细 | 0 | 1 | 2 | 0 | 2.67 |
Hyperfine has a consensus price target of $4.30, suggesting a potential upside of 400.00%. Given Hyperfine's higher possible upside, analysts plainly believe Hyperfine is more favorable than Echo Therapeutics.
HyperFine的普遍目标价为4.3美元,暗示潜在涨幅为400.00%。考虑到HyperFine的更高可能上行空间,分析师们显然认为HyperFine比Echo治疗公司更有利。
Summary
摘要
Hyperfine beats Echo Therapeutics on 5 of the 8 factors compared between the two stocks.
在两只股票之间的8个因素中,有5个因素超精细击败了Echo治疗公司。
About Echo Therapeutics
关于Echo Treateutics
(Get Rating)
(获取评级)
Echo Therapeutics, Inc. is a medical device company, which engages in the development of non-invasive, and wireless continuous glucose monitoring system for use in the diabetes outpatient market. It offers needle-free skin preparation device as a platform technology that allows for enhanced skin permeation enabling extraction of analytes, such as glucose and delivery of topical pharmaceuticals. The company was founded in 1989 and is headquartered in Iselin, NJ.
Echo治疗公司是一家医疗设备公司,致力于开发用于糖尿病门诊市场的非侵入性、无线连续血糖监测系统。它提供无针头皮肤准备设备作为平台技术,允许增强皮肤渗透性,从而能够提取葡萄糖等分析物并提供局部药物。该公司成立于1989年,总部设在新泽西州的伊塞林。
About Hyperfine
关于超精细
(Get Rating)
(获取评级)
Hyperfine, Inc. provides imaging, monitoring, and magnetic resonance imaging products. It offers Swoop Portable MR imaging system to address an unmet need in point-of-care medical imaging through a combination of hardware and software services. The company was incorporated in 2014 and is based in Guilford, Connecticut.
Hyperfiny,Inc.提供成像、监测和磁共振成像产品。它提供Swoop便携式磁共振成像系统,通过硬件和软件服务的组合来满足医疗点式医学成像方面未得到满足的需求。该公司成立于2014年,总部设在康涅狄格州吉尔福德。
Receive News & Ratings for Echo Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Echo Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
接受Echo治疗日报的新闻和评级-在下面输入您的电子邮件地址,通过MarketBeat.com的免费每日电子邮件时事通讯接收对Echo治疗公司和相关公司的最新新闻和分析师评级的每日简要摘要。